Lilly alters Alzheimer’s Trial Endpoint Ongoing Phase III Trial
In an unusual move, Eli Lilly has changed the endpoint of an ongoing Phase III trial that assess its experimental beta amyloid antibody solanezumab in patients with Alzheimer’s disease.
Shire to Launch Long-Acting ADHD Drug in the UK
Shire has rolled out their long-acting ADHD (attention deficit hyperactivity disorder) drug Intuniv nationwide. In doing so the treatment options for patients aged six to 17 years old in whom stimulant medicines are not suitable or are ineffective has been extended.
Clinical Professionals’ Acquisition by CPL
Yvette Cleland CEO of Clinical Professionals Ltd is delighted to announce its acquisition by Ireland’s leading employment services group, CPL Resources PLC. As Europe’s leading life science staffing company we strive to provide the highest quality service for both candidates and clients whilst priding ourselves in being innovators within the life science industry. The acquisition
Celgene reaches deal to acquire Receptos for $7.2 billion
It has been announced that Celgene, a biotechnology company, has signed an agreement to buy Receptos for $7.2 billion. This will result in a boost for its inflammation and immunology portfolio.
Initiatives Could Create 30,000 – 60,000 New UK Jobs, Claim BIA
The BioIndustry Association (BIA) has published a number of initiatives that they claim would rank the UK among the three largest biotech clusters in the world, and could create between 30,000 and 60,000 additional UK jobs. In addition to the increase jobs, the main objectives of the 10-year plan include a fourfold increase in the
UK Launches Innovative Medicines and MedTech Review
The UK government has announced an innovative medicines review and increased funding for the life sciences sector. The Innovative Medicines and MedTech Review has been created to see how new approaches to the development of drugs, diagnostics and devices, “based on precision medicine and emerging technologies, could speed up access to innovative products for NHS
Bayer Starts Phase II Clinical Trial of Riociguat
Bayer HealthCare has confirmed that they have begun a Phase II clinical trial of riociguat for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). Systemic sclerosis is a rare multisystem, autoimmune disease that results in the overproduction and abnormal growth of collagen, which causes fibrosis of the skin and internal organs. dcSSc is one of
Patent Law Amendment Could Increase UK Clinical Trials
A major change to UK patent law which took effect yesterday could help attract more clinical studies to the UK. The amendment to the patent law allows organisations to use a patented product when carrying out clinical trials, removing the risk of infringement claims. The amendment is an addition to the existing ‘Bolar Exemption’, a
Bristol-Myers Squibb Partners with Celgene to Test Cancer Combo
Celgene and Bristol-Myers Squibb have founded a clinical trial alliance for a potential new cancer combination therapy. As part of the alliance, the two companies will conduct a Phase I clinical study to assess the safety, tolerability and early efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo and Celgene’s chemotherapy Abraxane.
UCB Announces Positive Phase III Clinical Results for Brivaracetam
UCB has today announced positive topline clinical results for epilepsy drug, brivaracetam, from their most recent Phase III clinical study. The aim of clinical trial was to assess the effectiveness of brivaracetam as adjunctive treatment in adults not fully controlled despite treatment with one or two concomitant antiepileptic drugs, in comparison to placebo. Results of